USA – ILiAD Biotechnologies, a late-stage biotech development company dedicated to the prevention of disease caused by Bordetella pertussis, has announced the selection of Emmes Group to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1.
ILiAD’s decision to select Emmes Group , stems from the latter’s recognized expertise in vaccine development, coupled with their agility in managing complex clinical trials, robust local market presence, and integrated technology capabilities.
Emmes Group’s VaxTrials unit has previously demonstrated proficiency and clinical trial excellence through their successful support of ILiAD’s Phase II IB-201P BPZE1 study, which further solidified their reputation as a capable partner.
Moreover, the multiple Phase III studies are anticipated to be conducted across North America, Central and South America, the UK, and other global clinical sites.
This wide geographical coverage underscores the importance of the partnership between ILiAD and Emmes Group in ensuring comprehensive and effective trials.
Commenting on this significant agreement, Dr. Keith Rubin, CEO of ILiAD Biotechnologies, emphasized that selecting Emmes Group for their Phase III BPZE1 trials has been a carefully considered strategic decision.
This partnership is designed to ensure the highest standards of clinical research. Dr. Rubin highlighted that VaxTrials’ specialization in vaccines, alongside Veridix AI’s advanced technological capabilities, will be instrumental in executing ILiAD’s BPZE1 vaccine clinical development plan.
He underscored the critical role that these elements will play in the successful implementation of the trials.
In addition, Sastry Chilukuri, CEO of Emmes Group, expressed his honor and pleasure that ILiAD has chosen Emmes Group as its partner to continue the clinical development of BPZE1.
Chilukuri noted that they look forward to working closely with ILiAD’s clinical development team on this promising new vaccine.
This collaboration is expected to significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations, marking a pivotal step forward in the fight against pertussis.
Pertussis, commonly known as whooping cough, is a life-threatening disease caused by the highly contagious respiratory bacterium Bordetella pertussis.
According to the U.S. Centers for Disease Control and Prevention, pertussis affects approximately 16 million people globally each year, resulting in nearly 200,000 deaths.
Despite an estimated global vaccination coverage of 84%, current vaccines have failed to fully control pertussis epidemics, highlighting the urgent need for more effective solutions like BPZE1.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook
